This is a retrospective, multicenter study focused on patients with a known diagnosis of PMLBCL which experienced a CNS relapse during the course of their disease to obtain information about the clinical characteristics, the management at diagnosis and at each relapses , and the outcome of these cases. The aim of the study is to put together the large International series on CNS+ PMLBCL data, coming from 6 different countries , on clinical factors, anti-lymphoma therapy administered alone or concomitant with CNS prophylaxis , the information about the site of re biopsy when available , the dose intensity of lymphoma therapy received at relapse and the outcome of patients. Both patients treated in routine practice or within clinical trials will be considered. Moreover to better characterized the pathological features of this rare entity a central pathological review of the initial diagnosis and when available of for histological confirmed relapse will be considered.
Study Type
OBSERVATIONAL
Enrollment
45
Ospedale San Raffaele
Milan, Italy, Italy
Clinical characteristics 1
to describe the PMLBCL characteristics at diagnosis and at CNS relapse ( first relapse or second and subsequent recurrences) and the treatment received to describe the median time to CNS relapse to define prognostic factors of outcome of CNS relapse in PMLBCL patients
Time frame: 2 YEARS
Clinical characteristics 2
to correlate treatment strategy with survival end-points
Time frame: 2 YEARS
Clinical characteristics 3
to evaluate the Progression Free Survical ( PFS) after CNS events
Time frame: 2 YEARS
Clinical characteristics 4
to evaluate Overall Survival ( OS) after CNS relapse to centra! pathological reviewed the initial diagnosis and the relapse and to correlate biological and molecular factors with CNS recurrence
Time frame: 2 YEARS
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.